vs
Side-by-side financial comparison of DoorDash (DASH) and Regeneron Pharmaceuticals (REGN). Click either name above to swap in a different company.
DoorDash is the larger business by last-quarter revenue ($4.0B vs $3.6B, roughly 1.1× Regeneron Pharmaceuticals). Regeneron Pharmaceuticals runs the higher net margin — 20.2% vs 7.1%, a 13.1% gap on every dollar of revenue. On growth, Regeneron Pharmaceuticals posted the faster year-over-year revenue change (19.0% vs 8.3%). Regeneron Pharmaceuticals produced more free cash flow last quarter ($848.3M vs $355.0M). Over the past eight quarters, DoorDash's revenue compounded faster (23.9% CAGR vs 0.8%).
DoorDash, Inc. is an American company operating online food ordering and food delivery. It trades under the symbol DASH. With a 56% market share, DoorDash is the largest food delivery platform in the United States. It also has a 60% market share in the convenience delivery category. As of December 31, 2020, the platform was used by 450,000 merchants, 20 million consumers, and had over one million delivery couriers.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
DASH vs REGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.0B | $3.6B |
| Net Profit | $285.0M | $727.0M |
| Gross Margin | 39.8% | 89.6% |
| Operating Margin | 3.7% | 17.8% |
| Net Margin | 7.1% | 20.2% |
| Revenue YoY | 8.3% | 19.0% |
| Net Profit YoY | 47.7% | -10.1% |
| EPS (diluted) | $0.42 | $6.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.0B | $3.6B | ||
| Q4 25 | $4.0B | $3.9B | ||
| Q3 25 | $3.4B | $3.8B | ||
| Q2 25 | $3.3B | $3.7B | ||
| Q1 25 | $3.0B | $3.0B | ||
| Q4 24 | $2.9B | $3.8B | ||
| Q3 24 | $2.7B | $3.7B | ||
| Q2 24 | $2.6B | $3.5B |
| Q1 26 | $285.0M | $727.0M | ||
| Q4 25 | $213.0M | $844.6M | ||
| Q3 25 | $244.0M | $1.5B | ||
| Q2 25 | $285.0M | $1.4B | ||
| Q1 25 | $193.0M | $808.7M | ||
| Q4 24 | $141.0M | $917.7M | ||
| Q3 24 | $162.0M | $1.3B | ||
| Q2 24 | $-157.0M | $1.4B |
| Q1 26 | 39.8% | 89.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 3.7% | 17.8% | ||
| Q4 25 | 3.7% | 22.7% | ||
| Q3 25 | 7.5% | 27.3% | ||
| Q2 25 | 5.0% | 29.4% | ||
| Q1 25 | 5.1% | 19.5% | ||
| Q4 24 | 4.1% | 26.1% | ||
| Q3 24 | 4.0% | 31.7% | ||
| Q2 24 | -7.6% | 30.2% |
| Q1 26 | 7.1% | 20.2% | ||
| Q4 25 | 5.4% | 21.7% | ||
| Q3 25 | 7.1% | 38.9% | ||
| Q2 25 | 8.7% | 37.9% | ||
| Q1 25 | 6.4% | 26.7% | ||
| Q4 24 | 4.9% | 24.2% | ||
| Q3 24 | 6.0% | 36.0% | ||
| Q2 24 | -6.0% | 40.4% |
| Q1 26 | $0.42 | $6.75 | ||
| Q4 25 | $0.49 | $7.78 | ||
| Q3 25 | $0.55 | $13.62 | ||
| Q2 25 | $0.65 | $12.81 | ||
| Q1 25 | $0.44 | $7.27 | ||
| Q4 24 | $0.35 | $8.12 | ||
| Q3 24 | $0.38 | $11.54 | ||
| Q2 24 | $-0.38 | $12.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.5B | — |
| Total DebtLower is stronger | — | $2.0B |
| Stockholders' EquityBook value | $10.2B | $31.4B |
| Total Assets | $19.7B | $40.9B |
| Debt / EquityLower = less leverage | — | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.5B | — | ||
| Q4 25 | $4.4B | $8.6B | ||
| Q3 25 | $3.3B | $8.4B | ||
| Q2 25 | $3.9B | $7.5B | ||
| Q1 25 | $4.5B | $8.3B | ||
| Q4 24 | $4.0B | $9.0B | ||
| Q3 24 | $3.7B | $9.8B | ||
| Q2 24 | $3.4B | $9.8B |
| Q1 26 | — | $2.0B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $10.2B | $31.4B | ||
| Q4 25 | $10.0B | $31.3B | ||
| Q3 25 | $9.5B | $31.0B | ||
| Q2 25 | $8.9B | $29.9B | ||
| Q1 25 | $8.4B | $29.4B | ||
| Q4 24 | $7.8B | $29.4B | ||
| Q3 24 | $7.6B | $29.3B | ||
| Q2 24 | $7.2B | $28.2B |
| Q1 26 | $19.7B | $40.9B | ||
| Q4 25 | $19.7B | $40.6B | ||
| Q3 25 | $18.0B | $40.2B | ||
| Q2 25 | $16.9B | $38.2B | ||
| Q1 25 | $13.6B | $37.5B | ||
| Q4 24 | $12.8B | $37.8B | ||
| Q3 24 | $12.3B | $37.4B | ||
| Q2 24 | $11.8B | $36.1B |
| Q1 26 | — | 0.06× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $504.0M | $1.1B |
| Free Cash FlowOCF − Capex | $355.0M | $848.3M |
| FCF MarginFCF / Revenue | 8.8% | 23.5% |
| Capex IntensityCapex / Revenue | — | 6.4% |
| Cash ConversionOCF / Net Profit | 1.77× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $2.0B | $4.1B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $504.0M | $1.1B | ||
| Q4 25 | $421.0M | $1.2B | ||
| Q3 25 | $871.0M | $1.6B | ||
| Q2 25 | $504.0M | $1.1B | ||
| Q1 25 | $635.0M | $1.0B | ||
| Q4 24 | $518.0M | $1.3B | ||
| Q3 24 | $531.0M | $1.3B | ||
| Q2 24 | $530.0M | $354.0M |
| Q1 26 | $355.0M | $848.3M | ||
| Q4 25 | $367.0M | $922.0M | ||
| Q3 25 | $808.0M | $1.4B | ||
| Q2 25 | $438.0M | $925.4M | ||
| Q1 25 | $561.0M | $815.8M | ||
| Q4 24 | $486.0M | $1.1B | ||
| Q3 24 | $499.0M | $1.0B | ||
| Q2 24 | $507.0M | $173.5M |
| Q1 26 | 8.8% | 23.5% | ||
| Q4 25 | 9.3% | 23.7% | ||
| Q3 25 | 23.4% | 37.8% | ||
| Q2 25 | 13.3% | 25.2% | ||
| Q1 25 | 18.5% | 26.9% | ||
| Q4 24 | 16.9% | 28.1% | ||
| Q3 24 | 18.4% | 28.2% | ||
| Q2 24 | 19.3% | 4.9% |
| Q1 26 | — | 6.4% | ||
| Q4 25 | 1.4% | 6.4% | ||
| Q3 25 | 1.8% | 5.4% | ||
| Q2 25 | 2.0% | 6.0% | ||
| Q1 25 | 2.4% | 7.6% | ||
| Q4 24 | 1.1% | 5.3% | ||
| Q3 24 | 1.2% | 6.5% | ||
| Q2 24 | 0.9% | 5.1% |
| Q1 26 | 1.77× | 1.48× | ||
| Q4 25 | 1.98× | 1.39× | ||
| Q3 25 | 3.57× | 1.11× | ||
| Q2 25 | 1.77× | 0.82× | ||
| Q1 25 | 3.29× | 1.29× | ||
| Q4 24 | 3.67× | 1.38× | ||
| Q3 24 | 3.28× | 0.96× | ||
| Q2 24 | — | 0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DASH
Segment breakdown not available.
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
